Merger Pending

Passage Bio and Remix Therapeutics merger

Announced 24 Jun 2026

Advisers

Remix Therapeutics

Target

Legal adviser

Passage Bio

Acquirer

Legal adviser
Target
Remix Therapeutics
Acquirer
Passage Bio
Target based in
United States
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Drug Development, Oncology

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.